Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Immunogenicity of NVX-CoV2705
NCT07079670 · View on ClinicalTrials.gov ↗
Study Summary
This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study researchers will be closely monitoring participants for their immune response for 28 days and collecting safety data for 180 days after vaccination.
Conditions Studied
Interventions
- BIOLOGICAL NVX-CoV2705
Study Locations (10)
Texas
- Investigational Site Number US047 — Austin
- Investigational Site Number US073 — Tomball
Arizona
- Investigational Site Number US404 — Phoenix
Illinois
- Investigational Site Number US395 — Melrose Park
Kansas
- Investigational Site Number US406 — Lenexa
Louisiana
- Investigational Site Number US294 — Lafayette
Michigan
- Investigational Site Number US407 — Southfield
Nebraska
- Investigational Site Number US326 — Omaha
Ohio
- Investigational Site Number US381 — Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2026-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07079670
The ClinicalTrials.gov registry entry for NCT07079670 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 275 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention — of which NVX-CoV2705 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07079670 reports 10 study locations spanning 9 distinct geographic areas — top geographies include Texas, Arizona, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07079670 about?
NCT07079670 is a clinical study titled "Safety and Immunogenicity of NVX-CoV2705". This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to ...
What is the current status of trial NCT07079670?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2025-10-09. Estimated completion is 2026-06-16.
What conditions does trial NCT07079670 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2 Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07079670?
The interventions under investigation include: NVX-CoV2705 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07079670?
This trial is sponsored by Sanofi, which has 275 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07079670 being conducted?
This trial has 10 study locations across Arizona, Illinois, Kansas, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.